Liraglutide limited experience in Bahrain

Abstract EN

Background : Liraglutide is a Glucagon like peptide-1 (GLP-1) agonist which has been approved in the treatment of type 2 diabetes.

This drug has gained popularity because of its multiple advantages.

It controls blood glucose, reduces weight, regulates blood pressure and retains beta cell mass in the pancreas of diabetic patients.

The primary objective of this small intervention is to assess and compare the efficacy (change in HbA1c) after 26 weeks of adding Liraglutide to the pre-trial in subjects with inadequately controlled type 2 diabetes.

Design : A Prospective Clinical Trial.

Setting : A'Ali Health Center, Bahrain.

Method : Four patients who were residents of A’Ali, BMI ≥35 and uncontrolled diabetic on medication (HbA1c >7%) were recruited for twenty-six weeks clinical trial to receive Liraglutide.

The small cohort was followed up, and glycemic control and BMI were assessed pre and post trial.

Result : Obvious reduction in glycemic control and weight were noticed at the end of the 26 weeks.

Conclusion : In this small trial, Liraglutide is effective in improving glycemic control and reducing weight.